In the past decade many techniques have been described to evaluate the disease activity of atopic dermatitis. There is increasing evidence that some mediators or markers of eosinophils, mast cells, lymphocytes and other cell types may re¯ect the severity of atopic dermatitis (1 ± 7). In combination with clinical scores, such as the Severity Scoring of Atopic Dermatitis (SCORAD) index (8) , these markers may therefore be used as outcomes measures.
According to the literature, eosinophil cationic protein (ECP), a potent cytotoxic protein of eosinophils, appears to be involved in the pathogenesis of atopic dermatitis as indicated by elevated serum levels (2 ± 4, 9 ± 12). However, the small numbers of patients included in these studies limit the signi®cance of these observations. Additionally, it is still uncertain whether mediators released from mast cells, such as histamine, tryptase or tumour necrosis factor-a, can indicate the clinical activity of atopic dermatitis (12 ± 16) .
This study was designed to compare serum levels of two main mediators of eosinophils (ECP) and mast cells (tryptase) in a large cohort of randomly selected patients with atopic dermatitis and thereby assess these mediators for routine quality assurance during therapy in correlation to the clinical activity of the disease.
PATIENTS AND METHODS

Patients
All 117 patients (77 females, 40 males, 24.2¡15.6 years, range 1 ± 80 years) admitted to our hospital with atopic dermatitis within a 3-month period in 1997 were included in the study. The diagnosis was made according to the criteria of Hani®n & Rajka (17) . The status of the disease was evaluated on admission and at discharge using the SCORAD index (8) . This clinical index combines objective (extent and intensity) with subjective (loss of sleep, pruritus) parameters.
All patients were screened for serum concentrations of ECP and mast cell tryptase using speci®c immunoassays (Uni CAP ECP, geometric mean of healthy adults: 4.4 mg/l; Uni CAP Tryptase, geometric mean of healthy adults: 5.6 mg/l; Pharmacia & Upjohn, Freiburg, Germany). Venous blood (10 ml) was taken on admission and at discharge for the above purposes. Serum preparation and assays were performed according to the manufacturer's instructions. In addition, total IgE serum levels were measured (Uni CAP IgE, Pharmacia).
Method
Therapy for atopic dermatitis consisted of a combination of classical dermatological treatments, such as emollients, phototherapy and, as required, topical glucocorticosteroids of the fourth generation (18), combined with behavioural and educational elements (19, 20) . None of the 117 patients received systemic corticosteroids. According to the clinical status and individual experiences of the patients an individual interdisciplinary concept for treatment was initiated on admission. This study focused on the ef®cacy of the clinical outcome rather than on the ef®cacy of a single element of the therapeutic concept.
Statistics
The differences between the SCORAD index and the serum levels of the mediators before and after treatment were calculated using the Wilcoxon test. Differences associated with probability values of pv0.05 and pv0.02 were considered to be signi®cant and highly signi®cant, respectively. The correlation index (r) was calculated with the Spearman's rank correlation coef®cient matrix (SPSS 6.01, SPSS Inc., Chicago, IL, USA). Probability was assessed using Student's t-test.
RESULTS
SCORAD index
The SCORAD index (mean¡SD) was 48.0¡19.2 when patients were admitted to the hospital (range 5.7 ± 87.4). A statistically signi®cant difference between female and male Acta Derm Venereol 2000; 80: 284±286 patients was not observed. After a mean period of hospitalization of 24¡12 days the clinical status of all patients as measured by the SCORAD index had signi®cantly (pv0.001) improved by 85.1¡13.4%. Again, no differences were observed between female and male patients.
ECP and tryptase
We observed a signi®cant correlation (p~0.0014) between the clinical activity (as measured by the SCORAD index) and the ECP values on admission.
At discharge, serum ECP had decreased from 22.8¡19.7 mg/l to 15.4¡17.5 mg/l and this decrease was statistically signi®cant (pv0.001). There was no signi®cant correlation between the clinical improvement (DSCORAD) and the change in the ECP level (p~0.
Mean tryptase levels on admission were 5.2¡3.4 mg/l (range 1 ± 18.3). At the end of hospitalization tryptase levels were almost unchanged. There was no statistically signi®cant correlation between either tryptase levels and SCORAD values or between tryptase levels and ECP levels on admission (p~0.16 and p~0.05, respectively). No signi®cant regression between DSCORAD and Dtryptase was observed (r~0.006, p~0.30). DECP and Dtryptase also did not correlate signi®cantly (p~0.37).
DISCUSSION
This study demonstrates signi®cant improvement in the clinical status of a cohort of randomly selected patients suffering from atopic dermatitis as measured by the SCORAD index. This scoring system re¯ects the consensus of the European Task Force on Atopic Dermatitis (8) and has been widely used in the past (7, 9, 21, 22) . The combination of information concerning the intensity of skin involvement and measures of pruritus and sleep loss (visual analogue scale) has, however, been criticized (22) . Recently, the score has been used in a modi®ed fashion without including subjective symptoms (21) . As a parameter for quality assurance (23) the SCORAD index is therefore routinely used in our hospital in all patients with atopic dermatitis. The mean percentage improvement is regularly calculated to assess whether the therapeutic concept is ef®cacious for this group of patients.
Because the SCORAD index is complicated for routine clinical use (22) objective measures to record disease activity may be helpful. A number of serological parameters, such as soluble (s) IL-2 receptor (1, 10, 24), sCD14 (4), sCD30 (7), sICAM-1 (5) and sE-selectin (6, 25, 26) , have been investigated for association with the clinical score of atopic dermatitis. Numerous studies have focused on the role of ECP and have calculated a variable degree of correlation with the severity of the disease (2 ± 4, 9 ± 12). The present study showed a statistically signi®cant correlation between the serum levels of this mediator and actual clinical status in a larger population of patients with atopic dermatitis as measured by the SCORAD index. We did not observe a pronounced increase in ECP with increased disease severity. However, individual ECP concentrations on admission were in the range 2.9 ± 121 mg/l, which was comparable to the ranges found in previous studies with smaller numbers of patients (2 ± 4, 9 ± 12). Recently, Wolkerstorfer et al. (21) could not con®rm a signi®cant relationship between ECP serum levels and clinical activity in 40 children suffering from mild-to-moderate disease activity. With respect to the present results, determination of ECP levels as outcome parameters appears not to be suf®cient in patients with even severe forms of the disease. The lack of correlation between DSCORAD and DECP may indicate distinct ongoing eosinophil activity, even if the clinical status has improved. It is still uncertain whether high ECP serum levels at discharge are of prognostic value for predicting a relapse or whether they instead indicate an activation of other atopic diseases, such as allergic asthma or allergic rhinitis. The latter aspect has not been focused on in the present study. Longitudinal studies are therefore necessary to investigate changes in ECP concentrations during the interval of atopic dermatitis following discharge. Such studies should be combined with other measures of disease activity (22) .
Mast cell tryptase is a neutral protease which exerts a number of (pro)in¯ammatory activities (27) . Serum tryptase levels have been shown to correlate well with acute systemic mast cell activation, e.g. in anaphylactic reactions (27) . However, in atopic dermatitis subacute or chronic mast cell activation (e.g. late-phase reaction or piecemeal degranulation) is more relevant for the pathogenesis than acute mast cell degranulation (16, 28) . Serum tryptase levels as measured by the Uni Cap method did not signi®cantly correlate with disease activity. This con®rms previously published data from a radio immunoassay system for tryptase determination (12, 15) . However, evaluation of serum levels of a-protryptase may be worth studying in this disease (29) .
In summary, this study demonstrates that the combined determination of serum ECP levels and evaluation of the SCORAD index in atopic dermatitis is not superior to assessment of disease severity by the SCORAD index alone. Owing to the absence of a signi®cant correlation between DSCORAD and DECP in our population we conclude that evaluation of serum ECP levels on admission and at discharge may not be a valid tool for routine quality assurance in unselected patients with atopic dermatitis.
